Potential for therapeutic targeting of tumor stem cells

Cancer Science

Volumn 101, Issue 1, 2010, Pages 16-21

  Saini, Vaibhav ^a   Shoemaker, Robert H ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE; ALDEHYDE DEHYDROGENASE; ARSENIC TRIOXIDE; BETA CATENIN; CD133 ANTIGEN; CD15 ANTIGEN; CD24 ANTIGEN; CYCLOPAMINE; DOXORUBICIN; EPITHELIAL CELL ADHESION MOLECULE; FLICE INHIBITORY PROTEIN; HERMES ANTIGEN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MAMMALIAN TARGET OF RAPAMYCIN; MICROTUBULE ASSOCIATED PROTEIN 4; MULTIDRUG RESISTANCE PROTEIN 1; N2 [2 (3,5 DIFLUOROPHENYL) 2 HYDROXYACETYL] N1 (6,7 DIHYDRO 5 METHYL 6 OXO 5H DIBENZ[B,D]AZEPIN 7 YL)ALANINAMIDE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BCL 2; PROTEIN BCL XL; RETINOIC ACID; STAT PROTEIN; SULINDAC SULFIDE; TRANSFORMING GROWTH FACTOR BETA; VERY LATE ACTIVATION ANTIGEN 2; WNT PROTEIN;

ANTIGEN EXPRESSION; APOPTOSIS; BRAIN TUMOR; BREAST CANCER; CANCER CELL CULTURE; CANCER STEM CELL; CARCINOGENICITY; CELL HETEROGENEITY; CELL ISOLATION; CELL SURFACE; COLON CANCER; DNA DAMAGE; DNA REPAIR; DOWN REGULATION; DRUG TARGETING; EXTRACELLULAR MATRIX; GENE EXPRESSION PROFILING; HUMAN; HYPOXIA; LIVER CANCER; LUNG CANCER; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; STROMA CELL; TARGET CELL; UPREGULATION;

ALDEHYDE DEHYDROGENASE; ANIMALS; CELL SEPARATION; DRUG RESISTANCE, NEOPLASM; HUMANS; MICE; NEOPLASMS; NEOPLASTIC STEM CELLS;

EID: 71849094172     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01371.x     Document Type: Review

References (50)

1. Hamburger AW, Salmon SE. Primary bioassay of human tumor stem cells. Science 1977, 197:461-3.
2. Shoemaker RH, Wolpert-DeFilippes MK, Kern DH. Application of a human tumor colony-forming assay to new drug screening. Cancer Res 1985, 45:2145-53.
3. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997, 3:730-7.
4. Nasr R, Guillemin MC, Ferhi O. Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation. Nat Med 2008, 14:1333-42.
5. Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM, Morrison SJ. Efficient tumour formation by single human melanoma cells. Nature 2008, 456:593-8.
6. Freyer JP, Sutherland RM. Selective dissociation and characterization of cells from different regions of multicell tumor spheroids. Cancer Res 1980, 40:3956-65.
7. Yu SC, Ping YF, Yi L. Isolation and characterization of cancer stem cells from a human glioblastoma cell line U87. Cancer Lett 2008, 265(1):124-34.
8. Pollard SM, Yoshikawa K, Clarke ID. Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens. Cell Stem Cell 2009, 4:568-80.
9. Wright MH, Calcagno AM, Salcido CD, Carlson MD, Ambudkar SV, Varticovski L. Brca1 breast tumors contain distinct CD44 + /CD24- and CD133 + cells with cancer stem cell characteristics. Breast Cancer Res 2008, 10(1):R10.
10. Boman BM, Wicha MS. Cancer stem cells: a step toward the cure. J Clin Oncol 2008, 26:2795-9.
11. Vermeulen L, Todaro M, de Sousa Mello F. Single-cell cloning of colon cancer stem cells reveals a multi-lineage differentiation capacity. Proc Natl Acad Sci USA 2008, 105:13427-32.
12. Singh SK, Clarke ID, Terasaki M. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003, 63:5821-8.
13. Bidlingmaier S, Zhu X, Liu B. The utility and limitations of glycosylated human CD133 epitopes in defining cancer stem cells. J Mol Med 2008, 86:1025-32.
14. Ogden AT, Waziri AE, Lochhead RA. Identification of A2B5 + CD133- tumor-initiating cells in adult human gliomas. Neurosurgery 2008, 62:505-14. discussion 14-5
15. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003, 100:3983-8.
16. Yang YM, Chang JW. Current status and issues in cancer stem cell study. Cancer Invest 2008, 26:741-55.
17. Croker AK, Goodale D, Chu J. High aldehyde dehydrogenase and expression of cancer stem cell markers selects for breast cancer cells with enhanced malignant and metastatic ability. J Cell Mol Med 2008, doi
18. Ucar D, Cogle CR, Zucali JR. Aldehyde dehydrogenase activity as a functional marker for lung cancer. Chem Biol Interact 2009, 178:48-55.
19. Birnie R, Bryce SD, Roome C. Gene expression profiling of human prostate cancer stem cells reveals a pro-inflammatory phenotype and the importance of extracellular matrix interactions. Genome Biol 2008, 9:R83.
20. Shoemaker RH. The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer 2006, 6:813-23.
21. Li X, Lewis MT, Huang J. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 2008, 100:672-9.
22. Gillette JM, Nielsen-Preiss SM. Cancer stem cells: seeds of growth in osteosarcoma. Cancer Biol Ther 2009, 8:553-554.
23. Kvinlaug BT, Huntly BJ. Targeting cancer stem cells. Expert Opin Ther Targets 2007, 11:915-27.
24. Raguz S, Yague E. Resistance to chemotherapy: new treatments and novel insights into an old problem. Br J Cancer 2008, 99:387-91.
25. Sneddon JB, Werb Z. Location, location, location: the cancer stem cell niche. Cell Stem Cell 2007, 1:607-11.
26. Gordan JD, Thompson CB, Simon MC. HIF and c-Myc: sibling rivals for control of cancer cell metabolism and proliferation. Cancer Cell 2007, 12:108-13.
27. Keith B, Simon MC. Hypoxia-inducible factors, stem cells, and cancer. Cell 2007, 129:465-72.
28. Jensen KB, Jones J, Watt FM. A stem cell gene expression profile of human squamous cell carcinomas. Cancer Lett 2008, 272:23-31.
29. Jensen KB, Watt FM. Single-cell expression profiling of human epidermal stem and transit-amplifying cells: Lrig1 is a regulator of stem cell quiescence. Proc Natl Acad Sci USA 2006, 103:11958-63.
30. Gur G, Rubin C, Katz M. LRIG1 restricts growth factor signaling by enhancing receptor ubiquitylation and degradation. EMBO J 2004, 23:3270-81.
31. Laederich MB, Funes-Duran M, Yen L. The leucine-rich repeat protein LRIG1 is a negative regulator of ErbB family receptor tyrosine kinases. J Biol Chem 2004, 279:47050-6.
32. Andersen SS. Spindle assembly and the art of regulating microtubule dynamics by MAPs and Stathmin/Op18. Trends Cell Biol 2000, 10:261-7.
33. Eisenmann KM, McCarthy JB, Simpson MA. Melanoma chondroitin sulphate proteoglycan regulates cell spreading through Cdc42, Ack-1 and p130cas. Nat Cell Biol 1999, 1:507-13.
34. Majumdar M, Vuori K, Stallcup WB. Engagement of the NG2 proteoglycan triggers cell spreading via rac and p130cas. Cell Signal 2003, 15:79-84.
35. Iwasaki H, Suda T. Cancer stem cells and their niche. Cancer Sci 2009, 100:1166-72.
36. Johannessen TC, Bjerkvig R, Tysnes BB. DNA repair and cancer stem-like cells - potential partners in glioma drug resistance? Cancer Treat Rev 2008, 34:558-67.
37. Liu G, Yuan X, Zeng Z. Analysis of gene expression and chemoresistance of CD133 + cancer stem cells in glioblastoma. Mol Cancer 2006, 5:67.
38. Jin F, Zhao L, Zhao HY. Comparison between cells and cancer stem-like cells isolated from glioblastoma and astrocytoma on expression of anti-apoptotic and multidrug resistance-associated protein genes. Neuroscience 2008, 154:541-50.
39. Dean M. ABC transporters, drug resistance, and cancer stem cells. J Mammary Gland Biol Neoplasia 2009, 14(1):3-9.
40. Schatton T, Murphy GF, Frank NY. Identification of cells initiating human melanomas. Nature 2008, 451(7176):345-9.
41. Tirino V, Desiderio V, d'Aquino R. Detection and characterization of CD133 + cancer stem cells in human solid tumours. PLoS ONE 2008, 3:e3469.
42. Frank NY, Margaryan A, Huang Y. ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res 2005, 65:4320-33.
43. Harley CB. Telomerase and cancer therapeutics. Nat Rev Cancer 2008, 8:167-79.
44. Shay JW, Keith WN. Targeting telomerase for cancer therapeutics. Br J Cancer 2008, 98:677-83.
45. Gupta PB, Onder TT, Jiang G. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 2009, 138:645-59.
46. Bleau AM, Hambardzumyan D, Ozawa T. PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell 2009, 4:226-35.
47. Peacock CD, Wang Q, Gesell GS. Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma. Proc Natl Acad Sci USA 2007, 104:4048-53.
48. Saini V, Martyshkin DV, Mirov SB. An adenoviral platform for selective self-assembly and targeted delivery of nanoparticles. Small 2008, 4:262-9.
49. Saini V, Roth JC, Pereboeva L, Everts M. Importance of viruses and cells in cancer gene therapy. Adv Gene Mol Cell Ther 2007, 1:30-43.
50. Saini V, Zharov VP, Brazel CS, Nikles DE, Johnson DT, Everts M. Combination of viral biology and nanotechnology: new applications in nanomedicine. Nanomedicine 2006, 2:200-6.